A Phase II Trial of Temozolomide in Patients with Unresectable or Metastatic Soft Tissue Sarcoma

Cancer

Volumn 98, Issue 9, 2003, Pages 1942-1946

  Talbot, Susan M ^a   Keohan, Mary Louise ^a   Hesdorffer, Mary ^a   Orrico, Russell ^a   Bagiella, Emilia ^a   Troxel, Andrea B ^a   Taub, Robert N ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Chemotherapy; Phase II; Soft tissue sarcoma; Temozolomide

Indexed keywords

DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEADACHE; HEMOPTYSIS; HUMAN; INFECTION; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; FEMALE; HUMANS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; PROGNOSIS; SARCOMA; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 0142181101     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11730     Document Type: Article

References (22)

1. Greenlee R, Murray T, Bolden S, Wingo P. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
2. Brennan M, Casper E, Harrison L. Soft tissue sarcoma. In: DeVita VJ, Hellman S, Rosenberg S, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:1738-1788.
3. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11:1269-1275.
4. Antman K, Crowley J, Balcerzak SP, et al. An intergroup Phase III study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276-1285.
5. Mizuno N, Decker R. Alteration of DNA by 5-3-methyl-1-triazenolimidazole-4 carboxamide (NSC 407347). Biochem Pharmacol. 1976;25:2645-2647.
6. Stevens M, Newlands E. From triazines and triazenes to temozolomide. Eur J Cancer. 1993;29A:1045-1047.
7. Tentori L, Graziani G, Gllberti S, Lacal PM, Bonmassar E, D'Atri S. Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. Leukemia. 1995;9:1888-1895.
8. Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47:5846-5852.
9. Bower M, Newlands E, Bleehan N, et al. Multicentre CRC Phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40:484-488.
10. Yung WK, Albright RE, Olson J, et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
11. Friedman H. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol. 2000;27(3 Suppl 6):35-40.
12. Bleehen NM, Newlands ES, Lee SM, et al. Cancer research campaign Phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;13:910-913.
13. Middleton MR, Grob JJ, Aaronson N, et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma. J Clin Oncol. 2000;18:158-166.
14. Woll PJ, Judson I, Lee SM, et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 1999;35:410-412.
15. Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1991;2:307-309.
16. Van Oosterom AT, Judson I, Verweij J, et al. STI 571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC Phase I study. Proc Am Soc Clin Oncol. 2001;20:A2.
17. Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI 571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD 117). Proc Am Soc Clin Oncol. 2001;20:A1.
18. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-2037.
19. Casper ES, Waltzman RJ, Schwartz GK, et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. 1998;16:442-446.
20. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73:2506-2511.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
22. Van Glabbeke MM, Hogendoorn PCW, Mouridsen H, et al. Progression free rate as the principal end-point for Phase II trial on soft tissue sarcoma: what should be the target? A retrospective study of the EORTC Soft Tissue and Bone Sarcoma (STBSG) Database. Proc Am Soc Clin Oncol. 2001;20:A1413.